These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 22723515)

  • 21. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
    Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of recombinant human factor XIII in a cynomolgus monkey model of extracorporeal blood circulation.
    Ponce R; Armstrong K; Andrews K; Hensler J; Waggie K; Heffernan J; Reynolds T; Rogge M
    Toxicol Pathol; 2005; 33(6):702-10. PubMed ID: 16243775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the toxicology and pharmacokinetics of recombinant factor VIII Fc fusion protein in animals.
    Dumont JA; Loveday KS; Light DR; Pierce GF; Jiang H
    Thromb Res; 2015 Dec; 136(6):1266-72. PubMed ID: 26514955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamic model of interleukin-21 effects on red blood cells in cynomolgus monkeys.
    Overgaard RV; Karlsson M; Ingwersen SH
    J Pharmacokinet Pharmacodyn; 2007 Aug; 34(4):559-74. PubMed ID: 17516151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19.
    Davis CB; Hepburn TW; Urbanski JJ; Kwok DC; Hart TK; Herzyk DJ; Demuth SG; Leland M; Rhodes GR
    Drug Metab Dispos; 1995 Oct; 23(10):1028-36. PubMed ID: 8654189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical studies on synergistic effects of IL-1, IL-3, G-CSF and GM-CSF in cynomolgus monkeys.
    Krumwieh D; Weinmann E; Siebold B; Seiler FR
    Int J Cell Cloning; 1990 Jan; 8 Suppl 1():229-47; discussion 247-8. PubMed ID: 1691245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of estradiol on cortisol secretion in ovariectomized cynomolgus macaques (Macaca fascicularis).
    Stavisky RC; Watson SL; Anthony MS; Manuck SB; Adams MR; Kaplan JR
    Am J Primatol; 2003 May; 60(1):17-22. PubMed ID: 12766939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and adverse events following 5-day repeated administration of lenograstim, a recombinant human granulocyte colony-stimulating factor, in healthy subjects.
    Akizuki S; Mizorogi F; Inoue T; Sudo K; Ohnishi A
    Bone Marrow Transplant; 2000 Nov; 26(9):939-46. PubMed ID: 11100272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression, Purification, and Characterization of Interleukin-11 Orthologues.
    Sokolov AS; Kazakov AS; Solovyev VV; Ismailov RG; Uversky VN; Lapteva YS; Mikhailov RV; Pavlova EV; Terletskaya IO; Ermolina LV; Permyakov SE; Permyakov EA
    Molecules; 2016 Nov; 21(12):. PubMed ID: 27916836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of mass balance, pharmacokinetics and disposition of [14C(U)]- and [125I]recombinant human interleukin-2 in cynomolgus monkeys.
    Nadeau RW; Satoh H; Scheide S; Crowl R; Conroy R; Garland WA; Liberato DJ
    Drug Metab Dispos; 1995 Sep; 23(9):904-9. PubMed ID: 8565779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
    Stubenrauch K; Wessels U; Essig U; Vogel R; Schleypen J
    J Pharm Biomed Anal; 2010 Jun; 52(2):249-54. PubMed ID: 20083366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study.
    Nishimoto N; Yoshizaki K; Maeda K; Kuritani T; Deguchi H; Sato B; Imai N; Suemura M; Kakehi T; Takagi N; Kishimoto T
    J Rheumatol; 2003 Jul; 30(7):1426-35. PubMed ID: 12858437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
    Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
    Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toxicity of human recombinant interleukin-2 in rats. Pathologic changes are characterized by marked lymphocytic and eosinophilic proliferation and multisystem involvement.
    Anderson TD; Hayes TJ
    Lab Invest; 1989 Mar; 60(3):331-46. PubMed ID: 2784516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia.
    Fan Q; Leuther KK; Holmes CP; Fong KL; Zhang J; Velkovska S; Chen MJ; Mortensen RB; Leu K; Green JM; Schatz PJ; Woodburn KW
    Exp Hematol; 2006 Oct; 34(10):1303-11. PubMed ID: 16982323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimalarial pharmacodynamics and pharmacokinetics of a third-generation antifolate--JPC2056--in cynomolgus monkeys using an in vivo in vitro model.
    Edstein MD; Kotecka BM; Ager AL; Smith KS; DiTusa CA; Diaz DS; Kyle DE; Schiehser GA; Jacobus DP; Rieckmann KH; O'Neil MT
    J Antimicrob Chemother; 2007 Oct; 60(4):811-8. PubMed ID: 17646199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety pharmacology, toxicology and pharmacokinetic assessment of recombinant human omega-interferon produced from CHO-SS cells.
    Buckwold VE; Lang W; Scribner C; Blanchett D; Alessi T; Langecker P
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):62-70. PubMed ID: 16867173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C.
    Zeuzem S; Hopf U; Carreno V; Diago M; Shiffman M; Grüne S; Dudley FJ; Rakhit A; Rittweger K; Yap SH; Koff RS; Thomas HC
    Hepatology; 1999 Apr; 29(4):1280-7. PubMed ID: 10094976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone.
    Thygesen P; Andersen HS; Behrens C; Fels JJ; Nørskov-Lauritsen L; Rischel C; Johansen NL
    Growth Horm IGF Res; 2017 Aug; 35():8-16. PubMed ID: 28595133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and pharmacodynamics of pegylated interferon lambda-1 in cynomolgus monkeys.
    Byrnes-Blake KA; Pederson S; Klucher KM; Anderson-Haley M; Miller DM; Lopez-Talavera JC; Freeman JA
    J Interferon Cytokine Res; 2012 May; 32(5):198-206. PubMed ID: 22280056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.